How does your patient's
symptom control
stand up to a
24-hour world?

24-hour BREO for a 24-hour world

How does your patient's
asthma symptom
control stand up to a
24-hour world?

24-hour BREO for a 24-hour world
BREO is for adult patients with asthma uncontrolled on a long-term control medication (eg, ICS) or whose disease warrants an ICS/LABA (inhaled corticosteroid/long-acting beta2-adrenergic agonist).

BREO is NOT indicated for the relief of acute bronchospasm.



Lasting lung function improvement for a full 24 hours,
starting in 15 minutes*

*Median time to onset (100-mL increase from baseline in mean FEV1) was 15 minutes after beginning treatment


In a 12-week study in patients who were symptomatic on a mid- to high-dose ICS

BREO 100/25 (n=312) provided a statistically significant 108 mL (30%) improvement in least squares mean change from baseline in wm FEV1 (0-24 hours) compared with FF (fluticasone furoate) 100 mcg (n=288) (P<0.001) at Week 12."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1
  • wm FEV1: in a subset of patients, BREO 100/25 (n=108) demonstrated a numerically greater improvement in change from baseline in wm FEV1 (0-24 hours) compared with FF 100 mcg (n=106) of 116 mL (95% Cl: -5, 236; P=0.06) and a statistically significant 302-mL improvement (P<0.001) compared with placebo (n=95) at Week 12
  • Trough FEV1: there was a numerically greater change from baseline in trough FEV1 for BREO 100/25 (n=200) compared with FF 100 mcg (n=203) of 36 mL (95% Cl: -48, 120; P=0.405) and a statistically significant 172-mL improvement (P<0.001) compared with placebo (n=193) at Week 12
FEV1=forced expiratory volume in 1 second; ICS=inhaled corticosteroid.
Study Designs
More lung function data Adverse Reactions


Proven to reduce the RISK and RATE of exacerbations3*

In a 24- to 76-week study of patients with a history of asthma exacerbations

*Asthma exacerbation=a deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or on an inpatient hospitalization or ED visit due to asthma that required systemic corticosteroids.
Study Design
More exacerbation data Adverse Reactions


BREO - 24-hour lasting symptom control
without a second daily dose.

Based on a 12-week study of patients who remained symptomatic* on a mid- to high-dose ICS, BREO can offer

Study Design
Nighttime symptom data Adverse Reactions
Coverage Overview
Get information for your location Have confidence in coverage for BREO
Nationally, BREO has 4 million more commercial unrestricted lives than Symbicort*
*Managed Markets Insight & Technology, LLC database as of April 2018
BREO Unrestricted Commercial Coverage 164 Million; Symbicort Unrestricted Commercial Coverage 160 Million.
Patients are reimbursed from a health plan with no accompanying step edits or prior authorizations.
Individual access may vary by geography and plan benefit design.
“Unrestricted coverage” means reimbursement from a health plan without accompanying step edits or prior authorizations. Commercial lives calculation does not include patient lives associated with Indian Health Services or Department of Veterans Affairs.
What you need to know about this formulary information
Formulary status may vary and is subject to change. Formulary comparisons do not imply comparable indications, safety, or efficacy. This is not a guarantee of partial or full coverage or payment. Consumers may be responsible for varying out-of-pocket costs based on an individual’s plan and its benefit design. Each plan administrator determines actual benefits and out-of-pocket costs per its plan’s policies. Verify coverage with plan sponsor.

The brands listed, with the exception of BREO and ELLIPTA, are trademarks or registered trademarks of their respective owners and are not trademarks of the GSK group of companies. The makers of these brands are not affiliated with and do not endorse GSK or its products.

Formulary coverage
Looking for a savings offer?
Subject to eligibility. Restrictions apply.

Looking for BREO: Triple Therapy?

Learn more